SPL-707

Cell experiment:

DNA vectors encoding human Notch1-VP16-Gal4 fusion protein and a Gal4-luciferase reporter for the γ-secretase RGA, or human SPPL2a, VP16-TNFa(aa1-76)-NTF substrate, and the Gal4-luciferase reporter plasmid for the SPPL2a RGA, are transiently transfected in HEK293 cells using FuGENE. After transfection, the cell suspensions are diluted and distributed to white solid 384-well plate at 10000 cells/50 μL/well. After 3 h, 200 nL of SPL-707 in DMSO is stamped into the wells in concentration response covering final inhibitor concentrations of 10 μM to 0.3 nM in triplicate. Subsequently, plates are incubated for 24 h at 37°C, 5% CO2 in a humidified incubator before the addition of 30 μL Bright Glo. After incubation for 5 min at rt, luminescence is measured and IC50 values are determined by plotting compound concentration vs normalized luminescence values[1].

Animal experiment:

Rats[1]Female Lewis rats receive SPL-707 (1, 3, 10, and 30 mg/kg b.i.d.; first dose at 0 h, second dose at 8 h). Then 16 h after the second dose (24 h in total), inhibition of SPPL2a is assessed by measuring CD74/p8 accumulation in blood and splenocyte extracts by Western blot analysis[1].Mice[1] Mice receive single oral doses of 150 mg/ kg 31 or 1, 3, 10, and 30 mg/kg 40. Then 16 h after dosing, inhibition of SPPL2a is assessed by measuring CD74/p8 accumulation in splenocyte lysates by Western blot analysis[1].

References:

[1]. Velcicky J, et al. Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo. J Med Chem. 2018 Feb 8;61(3):865-880.